Entity Address, City or Town Entity Address City Or Town Pending Litigation Pending Litigation [Member] Other current liabilities Increase Decrease In Other Current Liabilities Fair Value Disclosures [Abstract] Payment for additional commitment fees Payment For Additional Commitment Fees Payment for additional commitment fees. Earnings Per Share [Abstract] Level 1 Fair Value Inputs Level1 [Member] Issuance of common stock, net of issuance costs Stock Issued During Period Value New Issues Shares value might be issued under agreement Shares value might be issued under agreement Shares Value Might Be Issued Under Agreement Shares value might be issued under agreement. Research and Development Expenses Research And Development Expense Policy Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Dividend rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Operating lease discount rate Lessee Operating Lease Discount Rate Fair Value Measurement Fair Value Disclosure Item Amounts [Domain] Amendment Flag Amendment Flag Proceeds from SWK Second Term Loan, net of warrant allocation and lender fees Proceeds From Issuance Of SWK Second Term Loan Proceeds From Issuance Of SWK Second Term Loan Fair value of options vested Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 Number of common stock authorized for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Subsequent Event Type Subsequent Event Type [Domain] Cash, FDIC insured amount Cash F D I C Insured Amount Waiver and Agreement Waiver And Agreement [Member] Waiver and agreement. Litigation Case Litigation Case Type [Domain] Lenders Party and SWK Funding LLC Lenders Party And S W K Funding L L C [Member] Lenders Party and SWK Funding LLC. Goodwill, Ending Balance Goodwill, Beginning Balance Goodwill, Total Goodwill Goodwill Percentage of royalty revenue received Percentage Of Royalty Revenue Received Percentage of royalty revenue received. Operating lease right of use asset Operating Lease Right Of Use Asset Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Operating Lease Liability Statement Of Financial Position Extensible List Number of business days for repurchase of convertible note Number of Business Days For Repurchase of Convertible Note Number of business days for repurchase of convertible note. Document Quarterly Report Document Quarterly Report Debt Instrument [Table] Debt Instrument [Table] Equity, Fair Value Disclosure, Total Fair value of warrant Equity Fair Value Disclosure Net proceeds from offering Net Proceeds From Offering Net proceeds from offering. Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List SWK Credit Agreement SWK Credit Agreement [Member] SWK Credit Agreement. Less effects of discounting Lessee Operating Lease Liability Undiscounted Excess Amount Pre-funded Warrant Prefunded Warrant Member Prefunded warrant member. Basic and Diluted Net Loss per Common Share Earnings Per Share Policy [Text Block] Cash payment received Cash Payment Received Cash payment received. Statement [Table] Statement [Table] Other non-current liabilities Operating Lease Liability Noncurrent Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Change In Accounting Principle Accounting Standards Update Immaterial Effect Litigation Status Litigation Status [Axis] Operating lease, cash payment made Operating Lease Payments LIBOR London Interbank Offered Rate L I B O R [Member] Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred stock, shares outstanding Preferred Stock Shares Outstanding Grant of inducement awards and reserved, shares Common Stock Capital Shares Reserved For Future Issuance Additional amount of accordion commitment Debt Instrument Maximum Incremental Facility Debt instrument, maximum incremental facility. Lincoln Park Lincoln Park Capital Fund L L C [Member] Lincoln park capital fund LLC. Post-modification Marathon Convertible Note Post-modification Marathon Convertible Note [Member] Post-modification marathon convertible note. Number of shares, company may sell on any single business day Number Of Common Stock May Sell In Single Business Day Number of common stock may sell in single business day. Fair value of the commitment fee shares, recorded to general and administrative expense along with other costs incurred Fair Value Of Commitment Fee Shares Fair value of commitment fee shares. Threshold number of calendar days to regain compliance Threshold Number Of Calendar Days To Regain Compliance Threshold number of calendar days to regain compliance. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Repayment Occurs On Or After May 16, 2023 But Prior to June 16, 2023 Repayment Occurs On Or After May 16 2023 But Prior to June 16 2023 [Member] Repayment Occurs On Or After May 16 2023 But Prior to June 16 2023. 2013 Stock Incentive Plan Two Thousand Thirteen Stock Incentive Plan [Member] Two thousand thirteen stock incentive plan. Percentage of option to capitalize Percentage Of Option To Capitalize Percentage of option to capitalize. Product and Service [Axis] Debt issuance costs incurred Debt Issuance Costs Incurred Debt issuance costs incurred. Debt Debt Policy [Text Block] Percentage of payment net profit territory Percentage Of Payment Net Profit Territory Percentage of payment net profit territory. Accrued employee bonus and vacation Employee-related Liabilities, Current Employee-related Liabilities, Current, Total Interest and other income (expense), net Interest And Other Expense Income Net Interest and other (expense) income, net. Leases Lessee Operating Leases [Text Block] Accrued precommercial costs Accrued Pre Commercial Costs Current Accrued pre-commercial costs current. Operating lease, weighted average remaining lease term Operating Lease Weighted Average Remaining Lease Term1 Offering closed date Offering Closing Date Offering Closing Date Total liabilities and stockholders’ deficit Liabilities And Stockholders Equity Inventory Inventory, Policy [Policy Text Block] Plan Name Plan Name [Domain] Other current liabilities Other Liabilities Current Line of Credit Facility, Lender Line Of Credit Facility Lender [Domain] Raw materials Inventory, Raw Materials, Gross Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Change In Accounting Principle Accounting Standards Update Adopted Development and commercial launch costs Development And Commercial Launch Costs Development and commercial launch costs. Entity Incorporation, State or Country Code Entity Incorporation State Country Code Amendment of Newton Lease Amendment Of Newton Lease Agreement [Member] Amendment of Newton Lease Agreement. Income Statement [Abstract] Percentage of prepayment, prior to March 4, 2025 Debt Instrument Prepayment Percentage Due Three Year Debt instrument prepayment percentage due three year. 2010 Stock Incentive Plan Two Thousand Ten Plan [Member] 2010 Plan. Collaboration Agreement Collaboration Agreement [Member] Collaboration agreement. Nature of Operations and Basis of Presentation Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Total current liabilities Current liabilities Liabilities Current Other assets: Other Assets [Abstract] Outstanding common stock beneficially owning percentage Outstanding Common Stock Beneficially Owning Percentage Outstanding common stock beneficially owning percentage. 2025 Lessee Operating Lease Liability Payments Due Year Three Loss Contingency Nature Loss Contingencies By Nature Of Contingency [Axis] Accounts payable and accrued expenses. Accounts Payable And Accrued Expenses [Member] Accounts Payable and Accrued Expenses Recurring Fair Value Measurements Recurring [Member] Quarterly over Remaining Three Years Share Based Compensation Award Tranche Two [Member] Weighted Average Exercise Price, Exercisable at end of the period Class Of Warrant Or Right Exercisable Exercise Price Of Warrants Class of warrant or right exercisable exercise price of warrants. Income Taxes Income Tax Policy [Text Block] Principal amortization payments Debt Instrument Amortization Payments Debt instrument amortization payments. Preferred stock, shares authorized Preferred Stock Shares Authorized Changes in fair value Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring, Basis, Liability Accrued Interest Expense And Basis, Liability, Period Increase Decrease Fair value, measurement with unobservable inputs reconciliation, recurring, basis, liability accrued interest expense and basis, liability, period increase (decrease). Upfront non-refundable payment received Upfront Non Refundable Payment Received Upfront non-refundable payment received. Repayment Occurs On Or After April 16, 2023 But Prior to May 16, 2023 Repayment Occurs On Or After April 16 2023 But Prior to May 16 2023 [Member] Repayment Occurs On Or After April 16 2023 But Prior to May 16 2023. Prefunded and Common Warrant Prefunded And Common Warrant Member Prefunded and common warrant member. Investment, Name Equity Method Investee Name [Domain] Variable Rate Variable Rate [Axis] Going Concern Substantial Doubt About Going Concern [Text Block] Entity Small Business Entity Small Business Oregon OREGON Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Amortizing date of Principal payment Debt Instrument Periodic Payment Principal Commencing Date Debt instrument periodic payment principal commencing date. ASU No. 2020-06 Accounting Standards Update202006 [Member] SWK Warrants SWK Warrant S W K Warrant [Member] SWK warrant. Development payments Development Payments Development payments. Number of business days for payment in full of all senior indebtedness Number of Business Days For Payment in Full of all Senior Indebtedness Number of business days for payment in full of all senior indebtedness. Square feet of office space leased Area Of Land Financial Advisor Financial Advisor [Member] Financial advisor. Total current assets Assets Current Debt issuance costs recognized as expense Debt Issuance Costs Recognized As Expense Debt issuance costs recognized as expense. Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Schedule Of Significant Accounting Policies [Line Items] Schedule Of Significant Accounting Policies [Line Items] Schedule of significant accounting policies. 2022 (remaining) Lessee Operating Lease Liability Payments Remainder Of Fiscal Year Stockholders Derivative Action Stockholders Derivative Action [Member] Stockholders derivative action. Weighted Average Number of Shares Outstanding, Basic, Total Weighted average common shares outstanding - basic Weighted Average Number Of Shares Outstanding Basic Reimbursement payment Reimbursement Payment Reimbursement Payment. Debt related expense commitment fee Debt Related Commitment Fees and Debt Issuance Costs City Area Code City Area Code Line of credit facility, additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Line of credit facility, additional borrowing capacity. Aggregate Intrinsic Value, Options outstanding at beginning of period Aggregate Intrinsic Value, Options outstanding at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Number of Shares, Options Cancelled/forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Proceeds from SWK Second Term Loan, net of warrant allocation and lender fees Proceeds from Second Term Loan, Net of Warrant Allocation and Lender Fees Proceeds from second term loan, net of warrant allocation and lender fees. Total liabilities Liabilities Private Placement Private Placement [Member] Document Period End Date Document Period End Date Common stock offering costs Payments Of Stock Issuance Costs Second Development Payment Second Development Payment [Member] Second Development Payment. Share-based compensation arrangement by share-based payment award, percentage of outstanding our common stock Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum Weighted average grant date fair value of options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Debt instrument, shares upon conversion of original principal amount Debt Conversion, Converted Instrument, Shares Issued Proceeds from issuance of common stock and warrants, net of issuance costs Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. One-year Anniversary of the Grant Date Share Based Compensation Award Tranche One [Member] Statistical Measurement Range [Axis] Second Term Loan Second Term Loan [Member] Second term loan. Other current assets Other Assets Current Original Term Loan Original Term Loan [Member] Original term loan. Subsequent Event [Line Items] Subsequent Event [Line Items] Proceeds from Marathon Convertible Notes, net of lender fees Proceeds from Secured Convertible Notes, net of lender fees Proceeds From Convertible Debt License Agreement Licensing Agreements [Member] Accounts Payable And Accrued Liabilities Current [Abstract] Remained available under facility Amount of Remained Available Under Facility Amount of remained available under facility. Total assets Assets March 2023 Offering March Two Thousand Twenty Three Offering Member March two thousand twenty three offering member. Earnings Per Share, Diluted, Total Net loss per share - diluted Earnings Per Share Diluted Schedule of Number of Shares of Common Stock Underlying Potentially Dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Beginning Balance Ending Balance Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Accrued contract manufacturing Accrued Contract Manufacturing Costs Current Accrued contract manufacturing costs current. Entity Address, Postal Zip Code Entity Address Postal Zip Code Number of patent applications Number Of Patent Applications Number of patent applications. Document Fiscal Period Focus Document Fiscal Period Focus Clinical Trial and Preclinical Study Expenses Clinical Trials And Preclinical Study Expenses Policy [Text Block] Clinical trials and preclinical study expenses. Cost of debt issuance Costs of debt issuance Costs Of Debt Issuance Costs of debt issuance. Debt instrument, maturity date, description Debt Instrument Maturity Date Description Relief Relief Therapeutics Holding AG Relief Therapeutics Holding A G [Member] Relief Therapeutics Holding AG. Deferred financing costs Deferred Offering Costs Preferred stock, $0.0001 par value; authorized 10,000,000 shares; none issued and outstanding Preferred Stock Value APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Convertible note payable, at fair value Convertible note payable, current, at fair value Convertible Notes Payable, Current Counterparty Name Repurchase Agreement Counterparty Name [Domain] Payment of settlement plus legal fees and costs in excess of retention (deductible) amount Payment Of Settlement Plus Legal Fees And Costs In Excess Of Retention Deductible Amount Payment of settlement plus legal fees and costs in excess of retention (deductible) amount. SWK and Holders S W K And Holders [Member] SWK and Holders. Lenders Party and SWK Funding LLC Lenders Party And SWK Funding LLC [Member] Lenders Party and SWK Funding LLC. Combined purchase price for one Share and one Common Warrant Combined Purchase Price for One Share and One Common Warrant Combined purchase price for one Share and one common warrant. Total lease liabilities as of September 30, 2022 Total lease liabilities Operating lease liability Operating Lease Liability Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Options to purchase common stock Options To Purchase Common Stock [Member] Options to purchase common stock. Short-Term Debt, Type Short Term Debt Type [Axis] Emory University Emory University [Member] Emory University. Statement Of Financial Position [Abstract] March 2023 Offering warrants March 2023 Offering Warrants [Member] March 2023 Offering Warrants [Member] Amount remained available under facility Amount remained available under facility Remaining Available Amount Of Common Stock Issuable Under Sales Agreement Remaining available amount of common stock issuable under sales agreement. Entity File Number Entity File Number Proceeds from Original Term Loan, net of warrant allocation and lender fees Proceeds From Original Term Loan Net Of Warrant Allocation And Lender Fees Proceeds from original term loan net of warrant allocation and lender fees. Scenario Scenario Unspecified [Domain] Prepaid expenses Increase Decrease In Prepaid Expense Gross proceeds from issuance or sale of equity, debt and/or hybrid securities, loans or other financing Gross Proceeds from Issuance or Sale of Equity Debt Hybrid Securities loans or Other Financing Gross proceeds from issuance or sale of equity debt hybrid securities loans or other financing. Statement Of Cash Flows [Abstract] Pre-Funded Warrants issued Warrant issued to purchase common stock Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Revenue Recognition and Accounting for Collaboration Agreements Revenue Recognition And Accounting For Collaboration Agreements Policy [Text Block] Revenue recognition and accounting for collaboration agreements. Net profit split ratio based on territory Net Profit Split Ratio Based On Territory Net profit split ratio based on territory. Proceeds from second tranche of development payments subject to new drug application Proceeds From Second Tranche Of Development Payments Subject To New Drug Application Proceeds from second tranche of development payments subject to new drug application. Proceeds from issuance of debt Proceeds from Issuance of Debt Accrued interest expense Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Accrued Interest Expense Fair value measurement with unobservable inputs reconciliations recurring basis liability accrued interest expense Geographical Segment Geographical [Domain] Statistical Measurement Range [Member] Statement Of Stockholders Equity [Abstract] Sale of Stock Subsidiary Sale Of Stock [Axis] Loss Contingency Accrual, Ending Balance Loss Contingency Accrual, Beginning Balance Proposed settlement as a loss in accrued expenses Loss Contingency Accrual At Carrying Value Legal Entity Legal Entity [Axis] Beneficially ownership percentage Equity Method Investment Ownership Percentage Secured Convertible Note Purchase Agreement Secured Convertible Note Purchase Agreement [Member] Secured Convertible Note Purchase Agreement. Potential proceeds from development payments subject to acceptance of new drug Potential Proceeds From Development Payments Subject To Acceptance Of New Drug Potential proceeds from development payments subject to acceptance of new drug. Subsequent Events [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Pre-Funded Warrants Pre-Funded Warrants [Member] Pre-Funded Warrants. Weighted Average Remaining Contractual Term, Options exercisable at end of period Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Proceeds from issuance of common stock, net of issuance costs Proceeds from issuance of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Collaboration and License Agreement Proposed Collaboration and License Agreement Collaboration And License Agreement [Member] Collaboration and license agreement. Issuance of common stock, gross sale price per share Stock Issued Gross Sale Price Per Share Stock issued, gross sale price per share. Long-Term Debt, Type Longterm Debt Type [Axis] Lease agreement date Lease Agreement Date Lease agreement date. Schedule of Property and Equipment Property Plant And Equipment [Text Block] Development payments subject new drug application Development Payments Subject To New Drug Application Development payments subject to new drug application. Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Line of credit facility, maximum borrowing capacity Line Of Credit Facility Maximum Borrowing Capacity Summary of Warrants Issued Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Loss Contingency, Nature Loss Contingency Nature [Domain] Change in fair value of debt instruments gain (loss) Changes in fair value of debt instruments gain (loss) Changes In Fair Value Of Debt Instruments Changes in fair value of debt instruments. Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Non-cash changes in fair value of debt, (gain) loss Non-cash changes in fair value of debt Non Cash Changes In Fair Value Of Debt Non-cash changes in fair value of debt. Promissory Note Promissory Note [Member] Promissory note. Credit Facility Credit Facility [Domain] Subsequent Events Subsequent Events [Text Block] Newton Lease Newton Lease [Member] Newton lease. Total weighted average shares of common stock and potentially dilutive shares Weighted average common shares outstanding - diluted Weighted Average Number Of Diluted Shares Outstanding Credit Facility Credit Facility [Axis] Percentage of aggregate revenue as royalty payments Percentage Of Aggregate Revenue Percentage of aggregate revenue. Portion at Fair Value Measurement [Member] [Default] Fair Value Disclosure Item Amounts [Default] Portion At Fair Value Fair Value Disclosure [Member] Computer Hardware and Software Computer Equipment [Member] General and Administrative General And Administrative Expense [Member] Unrecognized compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Current Fiscal Year End Date Current Fiscal Year End Date Depreciation, Total Depreciation Depreciation Upfront nonrefundable payment Upfront Nonrefundable Payment Upfront Nonrefundable Payment. Other non-current assets Other Assets Noncurrent Issuance of common stock for commitment fee, shares Issuance of common stock for commitment fee, shares Stock Issued During Period For Commitment Fee Shares Stock issued during period for commitment fee shares. Entity Address, Address Line One Entity Address Address Line1 Loan Received Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Loan Received Fair value measurement with unobservable inputs reconciliations recurring basis liability loan received. SWK Loans payable, current, at fair value SWK Loans Payable Current At Fair Value Current Swk loans payable current at fair value current. Royalty payments on aggregate revenue cap amount Royalty Payments On Aggregate Revenue Cap Amount Royalty payments on aggregate revenue cap amount. Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Agreement entered date Agreement Entered Month And Year Agreement entered month and year. Warrants Issued to SWK Warrants Issued To S W K [Member] Warrants issued to swk. preclinical or clinical study expense. Preclinical Or Clinical Study Expense Preclinical or clinical study expense At-the-Market Facility At-the-Market Facility At The Market Facility [Member] At The Market Facility. Number of days required for cash balance Number Of Days Required For Cash And Cash Equivalents Balance Number of days required for cash and cash equivalents balance. Lease expiration date Lease Expiration Date1 Lender Party and Marathon Lender Party And Marathon [Member] Lender Party and Marathon. Income Tax Expense (Benefit), Total Income tax expense (benefit) Income Tax Expense Benefit Securities Purchase Agreement Securities Purchase Agreement [Member] Securities purchase agreement. Vesting Vesting [Axis] Preferred stock, shares issued Preferred Stock Shares Issued Balance Sheet Location [Domain] Lease commencement date Lease Commencement Date Lease commencement date. Payments to Acquire Property, Plant, and Equipment, Total Purchase of property and equipment Payments To Acquire Property Plant And Equipment Change in Accounting Principle, Accounting Standards Update, Adoption Date Change In Accounting Principle Accounting Standards Update Adoption Date Commitment fee percentage on term loan amount Line Of Credit Facility Commitment Fee Percentage Issuance of common stock, net of issuance costs, shares Issuance of common stock, net of issuance costs, shares Stock Issued During Period Shares New Issues Debt instrument repayment percentage on outstanding principal plus any and all paid-in-kind interest amount Debt Instrument Repayment Percentage On Outstanding Principal Plus Any And All Paid In Kind Interest Amount Debt instrument repayment percentage on outstanding principal plus any and all paid-in-kind interest amount. Deferred collaboration funding, current Deferred Collaboration Funding Current Deferred collaboration funding current. Potential proceeds from development payments subject to new drug application Potential Proceeds From Development Payments Subject To New Drug Application Potential proceeds from development payments subject to new drug application. Carrying Amount Carrying Reported Amount Fair Value Disclosure [Member] Assets: Assets Fair Value Disclosure [Abstract] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Liquidity Liquidity Policy [Text Block] Liquidity. Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Organization Consolidation And Presentation Of Financial Statement [Table] Organization Consolidation And Presentation Of Financial Statement [Table] Organization, consolidation and presentation of financial statement. Equity [Abstract] Fair value of loan Line Of Credit Facility Fair Value Of Amount Outstanding Revenue recognized Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized General and Administrative Expenses Selling General And Administrative Expenses Policy [Text Block] Repayment of promissory note of prior loan and interest Repayment of Promissory Note of Prior Loan Plus Interest Repayment of promissory note of prior loan plus interest. Weighted Average Exercise Price, Options Cancelled/forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Loss from operations Operating Income Loss Debt instrument, interest rate Debt Instrument Interest Rate Stated Percentage Lease, option to extend Lessee Operating Lease Option To Extend Noncurrent liability Liabilities, Noncurrent Liabilities, Noncurrent, Total Private Acer Private Acer [Member] Private Acer. Additional paid-in capital Additional Paid In Capital Common Stock Deferred collaboration funding Deferred Collaboration Funding Deferred collaboration funding. Scenario Statement Scenario [Axis] Accrued license fees Accrued License Fees Current Accrued license fees current. 2010 and 2013 Stock Incentive Plan Two Thousand Ten And Two Thousand Thirteen Stock Incentive Plan [Member] Two thousand ten and two thousand thirteen stock incentive plan. Accrued consulting Accrued Professional Fees Current January 1, 2021 January One Two Thousand And Twenty One [Member] January One Two Thousand and Twenty One. Class of Warrant or Right Class Of Warrant Or Right [Domain] Entity Filer Category Entity Filer Category Aggregate offering price of common stock Aggregate Offering Price Of Common Stock Issuable Under Sales Agreement Aggregate offering price of common stock issuable under sales agreement. Proceeds from issuance of common stock gross Proceeds From Issuance Of Common Stock Gross Proceeds from issuance of common stock gross. Total operating expenses Operating Expenses Entity Current Reporting Status Entity Current Reporting Status Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Total inventory Inventory Inventory, Net Lenders Party and SWK Lender Party And S W K [Member] Lender party and SWK. Schedule of Accrued Expenses Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Aggregate Intrinsic Value, Options exercisable at end of period Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Executive Officers and Employees Executive Officers And Employees [Member] Executive officers and employees. Second tranche of development payment, expiry date. Second Tranche Of Development Payment Expiry Date Second tranche of development payment, expiry date Third Term Loan Third Term Loan [Member] Third Term Loan. Stockholders' Deficit Stockholders Equity Note Disclosure [Text Block] Total stockholders’ deficit Beginning balance Ending balance Stockholders Equity Third SWK Warrant Third SWK Warrant [Member] Third SWK Warrant. Origination fees Loan Processing Fee Asset Class Fair Value By Asset Class [Axis] Entity Tax Identification Number Entity Tax Identification Number Income Statement Location Income Statement Location [Axis] Common stock, $0.0001 par value; authorized 150,000,000 shares; 16,373,611 and 14,310,244 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively Common Stock Value Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Retained Earnings Accumulated Deficit Termination agreement date Debt Instrument Termination Agreement Date Debt instrument termination agreement date. Manufacturing Equipment Equipment [Member] January 1, 2022 January One Two Thousand And Twenty Two [Member] January One Two Thousand and Twenty Two. Issuance of common stock and warrants, net of issuance costs Stock Issued During Period Value Stock And Warrants Stock issued during period value stock and warrants. Equity Components Statement Equity Components [Axis] Maximum amount of Common stock at time of sale, per regular purchase Maximum amount of Common stock at time of sale, per regular purchase Maximum Amount Of Common Stock At Time Of Sale Per Regular Purchase Maximum amount of common stock at time of sale, per regular purchase. Original Term Loan And Swk Loans Original Term Loan And SWK Loans [Member] Original term loan and SWK loans. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total Changes in fair value Adjustment to Fair Value Mark to Market Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease Weighted average remaining life Warrant Weighted Average Remaining Life Warrant weighted average remaining life. Schedule Of Significant Accounting Policies [Table] Schedule Of Significant Accounting Policies [Table] Schedule of significant accounting policies. Accounting Standards Update Type Of Adoption [Member] ASU No. 2016-13 Accounting Standards Update 2016-13 [Member] President and Chief Executive Officer and Member and Chairman Of Board Of Directors President And Chief Executive Officer And Member And Chairman Of Board Of Directors [Member] President And Chief Executive Officer And Member And Chairman Of Board Of Directors [Member] Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Percentage of term loan amount equal to commitment fee Percentage of Term Loan Amount Equal to Commitment Fee Percentage of term loan amount equal to commitment fee. Prepaid Expense, Current, Total Prepaid expenses Prepaid Expense Current Leases [Abstract] Minimum cash balance required by the loan covenants Minimum Cash Balance Required By Loan Covenants Minimum cash balance required by loan covenants. Entity Emerging Growth Company Entity Emerging Growth Company Operating expenses: Operating Expenses [Abstract] Debt instrument, description of variable rate basis Debt Instrument Description Of Variable Rate Basis Monthly principal payment Debt Instrument Monthly Payment Principal Debt instrument monthly payment principal. Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders equity. Debt instrument, periodic payment, principal Debt Instrument Periodic Payment Principal Proceeds allocated to Warrant Proceeds allocated to First SWK Warrant Adjustments To Additional Paid In Capital Warrant Issued Expected life (years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Secured Loan Secured Debt [Member] Undiscounted lease liabilities for years ending December 31,: Operating Lease Liabilities Payments Due [Abstract] Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Weighted Average Remaining Contract Term, Options Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract] Debt instrument, description Debt Instrument Description Document Transition Report Document Transition Report MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P. M A M Aardvark L L C And Marathon Healthcare Finance Fund L P [Member] MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P. Assets, Fair Value Disclosure, Total Assets, fair value Assets Fair Value Disclosure Total other income (expense), net Nonoperating Income Expense Accrued Expenses Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block] CARES act of 2020 aid loan amount C A R E S Act Of2020 Aid Loan Amount CARES act of 2020 aid loan amount. Issuance of common stock, price per share Issuance of common stock, net price per share Sale of Stock, Price Per Share Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Collaboration receivable Increase Decrease In Collaboration Receivable Increase decrease in collaboration receivable. Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List Liquidity covenant, accounts payable number of days past due Liquidity Covenant Accounts Payable Number of Days Past Due Liquidity covenant, accounts payable, number of days past due. Amortization of debt issuance costs Amortization of Debt Issuance Costs Repayment of outstanding balance of prior loan and interest Repayment Of Outstanding Balance Of Prior Loan Plus Interest Repayment of outstanding balance of prior loan and interest. Net loss Net loss Net Income Loss Weighted Average Weighted Average [Member] Other current liabilities Operating Lease Liability Current Schedule of Assets and Liabilities Measured at Fair Value Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Additional Paid-in Capital Additional Paid In Capital [Member] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Secured Convertible Notes Secured Convertible Notes [Member] Secured Convertible Notes. ASU No. 2021-04 Accounting Standards Update202104 [Member] Entity Registrant Name Entity Registrant Name Threshold equity value as per Nasdaq capital market listing standards Threshold Equity Value As Per Nasdaq Capital Market Listing Standards Threshold Equity Value as per Nasdaq Capital Market Listing Standards. Liabilities, Fair Value Disclosure, Total Liabilities, fair value Liabilities Fair Value Disclosure Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Number of shares, Granted during the period Class Of Warrant Or Right Granted In Period Class of warrant or right granted in period. Buy-Out percentage Buy Out Percentage Buy out percentage. Net Loss Per Share Earnings Per Share [Text Block] Deferred collaboration funding, non-current Deferred Collaboration Funding Non Current Deferred collaboration funding, non-current. Debt instrument, maturity date Debt Instrument Maturity Date Lessee Lease Description [Table] Lessee Lease Description [Table] Share-Based Payment Arrangement, Noncash Expense, Total Stock-based compensation Share Based Compensation Property and equipment, net Property and equipment, net Property Plant And Equipment Net Expected term of stock option granted to employees and directors, average contractual term and vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Award Type [Domain] Statement [Line Items] Statement [Line Items] Operating lease expense Operating Lease Expense Liabilities: Liabilities Fair Value Disclosure [Abstract] Collaboration agreement amount Collaboration Agreement Amount Collaboration Agreement Amount. Combined purchase price for one Pre-Funded Warrant and one Common Warrant Combined Purchase Price for One Pre-Funded Warrant and One Common Warrant Combined purchase price for one pre-funded warrant and one common warrant. Title of 12(b) Security Security12b Title Increase (Decrease) in Accounts Payable, Total Accounts payable Increase Decrease In Accounts Payable Common Stock Common Stock [Member] Options contractual term Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Equity Component Equity Component [Domain] Entity Address, State or Province Entity Address State Or Province Geographical Statement Geographical [Axis] Purchase of warrants Class Of Warrant Or Right Purchase Of Warrants Class of warrant or right purchase of warrants. Net increase in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Document Type Document Type Cash paid for interest Interest Paid Net Litigation Status Litigation Status [Domain] Additional Newton Lease Additional Newton Lease [Member] Additional newton lease. Entity Shell Company Entity Shell Company Number of shares, Outstanding at beginning of the period Number of shares, Outstanding at end of the period Class Of Warrant Or Right Outstanding Threshold price per share for issuance of shares under agreement Threshold Price Per Share For Issuance Of Shares Under Agreement Threshold price per share for issuance of shares under agreement. Inventory Increase (Decrease) in Inventories Increase (Decrease) in Inventories, Total Stock-based compensation expense Allocated Share Based Compensation Expense Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Uncertain tax positions, accruals Unrecognized Tax Benefits Interest On Income Taxes Accrued Security Exchange Name Security Exchange Name Accrued legal fees Accrued Legal Fees Current Accrued legal fees current. Goodwill Goodwill And Intangible Assets Policy [Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in operating activities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Unrecognized compensation expense remaining vesting period Share based compensation arrangement by share based payment award, Weighted average period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Weighted Average Remaining Contractual Term, Options outstanding at beginning of period Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Fair Value By Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Commitments And Contingencies Disclosure [Abstract] Accrued interest Interest Payable, Current Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Reconciliation of Undiscounted Lease Liabilities to Total Lease Liabilities Lessee Operating Lease Liability Maturity Table [Text Block] Deferred collaboration funding Increase Decrease In Deferred Collaboration Funding Increase decrease in deferred collaboration funding. Deferred collaboration funding, cash received Deferred Collaboration Funding Cash Received Deferred collaboration funding cash received. Summary of Option Activity under 2018 Plan, 2013 Plan and 2010 Plan Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Recently Adopted Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Common stock, shares outstanding Beginning balance, shares Ending balance, shares Common Stock Shares Outstanding Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt, Total Gains Losses On Extinguishment Of Debt Work in process Inventory, Work in Process, Gross Number of shares, Exercisable at end of the period Class Of Warrant Or Right Exercisable Class of warrant or right exercisable. Debt Debt Disclosure [Text Block] Level 2 Fair Value Inputs Level2 [Member] Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Offset to general and administrative expenses Offset To General And Administrative Expenses Offset to general and administrative expenses. Debt instrument repayment percentage on outstanding principal plus any and all paid-in-kind interest amount Debt instrument repayment percentage on outstanding principal amount Debt Instrument Repayment Percentage On Outstanding Principal Amount Debt instrument repayment percentage on outstanding principal amount. Commitments and Contingencies (Note 8) Commitments And Contingencies Common stock, shares issued Common Stock Shares Issued Term Loan Term Loan [Member] Term Loan. Variable Rate Variable Rate [Domain] Minimum Minimum Minimum [Member] Debt instrument, frequency of periodic payment Debt Instrument Frequency Of Periodic Payment Share-based compensation arrangement by share-based payment award, description Share Based Compensation Arrangement By Share Based Payment Award Description Threshold bid price per share for continued listing on nasdaq Threshold Bid Price Per Share For Continued Listing On Nasdaq Threshold bid price per share for continued listing on nasdaq. Payment of settlement amount Payment of Settlement Amount Payment of the settlement amount. Risk-free interest rate, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Issuance of common stock and warrants, net of issuance costs Stock Issued During Period Stock And Warrants Stock issued during period stock and warrants. Weighted Average Exercise Price, Options exercisable at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Total accrued expenses Accrued expenses Accrued Liabilities Current Debt Instrument Debt Instrument [Axis] Stockholders’ deficit: Stockholders Equity [Abstract] Foreign currency transaction (loss) gain Foreign Currency Transaction Gain (Loss), before Tax, Total Foreign Currency Transaction Gain Loss Before Tax SWK Credit Agreement S W K Credit Agreement [Member] SWK Credit Agreement. Counterparty Name Counterparty Name [Axis] Entity Address, Address Line Two Entity Address Address Line2 Foreign Currency Transactions Gain/(Loss) Foreign Currency Transactions And Translations Policy [Text Block] Award Type [Axis] SWK Loans S W K Loan [Member] S W K Loan. Subsequent Event Subsequent Event [Member] Accrued accounting, audit, and tax fees Accrued Accounting Audit And Tax Fees Current Accrued accounting, audit, and tax fees current. Debt Instrument, Fair Value Disclosure, Total Liabilities, fair value Debt Instrument Fair Value Other income (expense), net: Nonoperating Income Expense [Abstract] Research and development (net of collaboration funding of $718,410 and $2,999,371 in the three months ended March 31, 2023 and 2022 respectively) Research and Development Expense, Total Research And Development Expense Total undiscounted lease liabilities Lessee Operating Lease Liability Payments Due Modified Bend Lease Modified Bend Lease Agreement [Member] Modified bend lease agreement. Entity Central Index Key Entity Central Index Key Marathon Credit Agreement Marathon Credit Agreement [Member] Marathon Credit Agreement. Debt instrument, interest rate, increase Debt Instrument Interest Rate Increase Decrease Period of right of first refusal Period of Right of First Refusal Period of right of first refusal. Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value Roll Forward Remaining obligation Shares Value Remaining Obligation Under Agreement Shares value remaining obligation under agreement. Accounting Policies [Abstract] Share-based compensation arrangement by share-based payment award, expiration date Share Based Compensation Arrangement By Share Based Payment Award Expiration Date Minimum percentage of loan proceeds used to cover payroll costs eligible for loan forgiven Minimum Percentage Of Loan Proceeds Used To Cover Payroll Costs Eligible For Loan Forgiven Minimum percentage of loan proceeds used to cover payroll costs eligible for loan forgiven. Litigation Case Litigation Case [Axis] Total commitment Debt Instrument Maximum Borrowing Capacity Debt instrument, maximum borrowing capacity. Secured Convertible Notes Assumed Conversion of Accrued Interest Owed Secured Convertible Notes Assumed Conversion Of Accrued Interest Owed [Member] Secured convertible notes assumed conversion of accrued interest owed member. Proceeds from first tranche of development payments subject to new drug application Proceeds From First Tranche Of Development Payments Subject To New Drug Application Proceeds from first tranche of development payments subject to new drug application. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Threshold number of business days for market value of listed securities Threshold Number Of Business Days For Market Value Of Listed Securities Threshold number of business days for market value of listed securities Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Debt instrument amortization percentage Debt Instrument Amortization Percentage Debt instrument, amortization percentage. Measurement Frequency Fair Value By Measurement Frequency [Axis] Available for the grant of future awards Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Aggregate gross proceeds from offering Aggregate Gross Proceeds From Offering Aggregate gross proceeds from offering. Guarantee for substantive review food and drug application Guarantee For Substantive Review Food And Drug Application Guarantee for substantive review food and drug application. Subsequent Event [Table] Subsequent Event [Table] General and administrative (net of collaboration funding of $1,142,596 and $2,372,175 in the three months ended March 31, 2023 and 2022 respectively) General and Administrative Expense, Total General And Administrative Expense Organization Consolidation And Presentation Of Financial Statements [Abstract] Weighted Average Exercise Price, Options outstanding at beginning of period Weighted Average Exercise Price, Options outstanding at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Stockholders Equity [Table] Stockholders Equity [Table] Stockholders equity. Research and Development Research And Development Expense [Member] Scenario Forecast Forecast [Member] Conversion price Debt Instrument Convertible Conversion Price1 Threshold net income from continuing operations as per Nasdaq capital market listing standards Threshold Net Income From Continuing Operations As Per Nasdaq Capital Market Listing Standards Threshold net income from continuing operations as per nasdaq capital market listing standards. Deferred financing costs, current Deferred Costs, Current Deferred Costs, Current, Total Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Percentage of prepayment, on or after March 4, 2025, but prior to March 4, 2026 Debt Instrument Prepayment Percentage Due Four Year Debt instrument prepayment percentage due four year. Senior Convertible Notes Senior Convertible Notes [Member] Senior convertible notes. Accumulated Deficit Retained Earnings [Member] Weighted Average Exercise Price, Granted Class Of Warrant Or Right Granted Exercise Price Of Warrants Class of Warrant or right granted exercise price of warrants. Debt: Debt Instrument Fair Value Disclosure [Abstract] Percentage of prepayment, on or after March 4, 2026, but prior to March 4, 2027 Debt Instrument Prepayment Percentage Due Five Year Debt instrument prepayment percentage due year five year. Schedule of Estimate Fair Value of Stock Options Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Table [Text Block] Money Market Funds in Cash Equivalents Money Market Funds [Member] Marathon Convertible Notes Marathon Convertible Notes [Member] Marathon convertible notes. Milestone payment to be received Milestone Payment To Be Received Milestone payment to be received. Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Operating Lease Liability Current Statement Of Financial Position Extensible List Operating Lease Liability Current Statement Of Financial Position Extensible List SOFR Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Subtotal property and equipment, gross Property Plant And Equipment Gross Percentage of aggregate gross proceeds of offering equal to cash fee Percentage of Aggregate Gross Proceeds of Offering Equal to Cash Fee Percentage of aggregate gross proceeds of offering equal to cash fee. Clearing fees Clearing Fees Clearing fees. Share-based compensation arrangement by share-based payment award, Vesting percentage Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage Entity Interactive Data Current Entity Interactive Data Current Public float Entity Public Float Proceeds from development payments subject to acceptance of new drug application Proceeds from Development Payments Subject to Acceptance of New Drug Application Proceeds from development payments subject to acceptance of new drug application. Cash payment received Accretion Of Issuance Costs On Series A Convertible Redeemable Preferred Stock Accretion of issuance costs on Series A Convertible Redeemable Preferred stock 2023 Lessee Operating Lease Liability Payments Due Next Twelve Months Cash in excess of FDIC insured limit Cash Uninsured Amount March 2023 Offering March 2023 Offering [Member] March 2023 offering. Shares associated with Marathon Convertible Note Shares Associated with Marathon Convertible Note [Member] Shares Associated with Marathon Convertible Note [Member] Leasehold Improvements Leasehold Improvements [Member] Proceeds allocated to Warrant based on valuation Proceeds From Issuance Of Warrants Local Phone Number Local Phone Number JPMorgan Chase Bank, N.A J P Morgan Chase Bank N A [Member] JPMorgan Chase Bank, N.A. Share and Common Warrants Share And Common Warrants Member Share and common warrants member. Schedule of Numerator and Denominator used in Calculation of Basic and Diluted Net Loss Per Common Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Share-based compensation arrangement by share-based payment award, stock options vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Proceeds from additional equity issued or subordinated debt Proceeds from Additional Equity Issued or Subordinated Debt Proceeds from additional equity issued or subordinated debt. Debt Disclosure [Abstract] Additional equity issued or subordinated debt outstanding Additional Equity Issued or Subordinated Debt Outstanding Additional equity issued or subordinated debt outstanding. Bridge Loan and Convertible Note Financing Bridge Loan And Convertible Note Financing [Member] Bridge Loan and the Convertible Note Financing. Unvested restricted stock units. Unvested Restricted Stock Units [Member] Unvested Restricted Stock Units Number of Shares, Options exercisable at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Lender Name Line Of Credit Facility [Axis] Lease, existence of option to extend Lessee Operating Lease Existence Of Option To Extend Number of Shares, Options Granted Awards granted under the plan Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Reduced area of land Reduced Area Of Land Reduced area of land. Increase in Buy-Out percentage Increase in Buy Out Percentage Increase in buy out percentage. Other non-current liabilities Other Liabilities Noncurrent Schedule of Change in Fair Value Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Income Statement Location Income Statement Location [Domain] Property Plant And Equipment [Abstract] Organization Consolidation and Presentation of Financial Statement [Line Items] Organization Consolidation And Presentation Of Financial Statement [Line Items] Organization, consolidation and presentation of financial statement. Unvested restricted stock units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance Commitment fee payable Commitment Fee Payable Commitment fee payable. Inventory Disclosure [Abstract] Maximum percentage of shares may be issued or sold based on outstanding shares immediately prior to execution of agreement Maximum Percentage Of Shares May Be Issued Or Sold Based On Outstanding Shares Immediately Prior To Execution Of Agreement Maximum percentage of shares may be issued or sold based on outstanding shares immediately prior to execution of agreement. Number of share outstanding Number of Shares, Options outstanding at beginning of period Number of Shares, Options outstanding at end of period Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Debt Instrument, Name Debt Instrument Name [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total Accruals for interest or penalties related to income tax matters Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Class of Warrant or Right Class Of Warrant Or Right [Axis] Payment of debt and convertible debt issuance costs Payments Of Debt Issuance Costs Offset to research and development expenses Offset To Research And Development Expenses Offset to research and development expenses. 2024 Lessee Operating Lease Liability Payments Due Year Two Vesting Vesting [Domain] Earnings Per Share, Basic, Total Net loss per share - basic Earnings Per Share Basic Weighted Average Exercise Price, Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Assets Assets [Abstract] Increase (Decrease) in Accrued Liabilities, Total Accrued expenses Increase Decrease In Accrued Liabilities Risk-free interest rate, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum Debt instrument, principal amount Debt Instrument Face Amount If ACER-001 Approval does not Occur on or Before September 30, 2022 If A C E R001 Approval Does Not Occur On Or Before September302022 [Member] If ACER-001 Approval does not occur on or before September 30, 2022. Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Loan amortization commencing date Loan Amortization Commencing Date Loan amortization commencing date. Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Liabilities and Stockholders’ Deficit Liabilities And Stockholders Equity [Abstract] SWK Loans payable, non-current, at fair value Swk Loans Payable Current At Fair Value Noncurrent Swk loans payable current at fair value noncurrent. Antidilutive Securities, Name Antidilutive Securities Name [Domain] Development and commercialization services and reliefs right of profit percentage Development and Commercialization Services and Reliefs Right of Profit Percentage Development and commercialization services and reliefs right of profit percentage. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Profit Loss If ACER-001 Approval does not Occur on or Before December 31, 2022 If ACER001 Approval Does Not Occur On Or Before December 31 2022 [Member] If ACER001 approval does not occur on or before December 31 2022. Accrued contract research and regulatory consulting Accrued Contract Research And Regulatory Consulting Current Accrued contract research and regulatory consulting. Current assets: Assets Current [Abstract] Newton, Massachusetts MASSACHUSETTS Warrant, exercise price Weighted Average Exercise Price, Outstanding at beginning of the period Weighted Average Exercise Price, Outstanding at end of the period Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Percentage of royalty net sales received Percentage Of Royalty Net Sales Received Percentage of royalty net sales received. Marathon Convertible Note Purchase Agreement Marathon Convertible Note Purchase Agreement [Member] Marathon convertible note purchase agreement. Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Payment for funding fee for services Payment For Funding Fee For Services Payment for funding fee for services. Measurement Frequency Fair Value Measurement Frequency [Domain] Issuance of common stock and warrants, net of issuance costs, shares Stock Issued During Period Shares Stock And Warrants Stock issued during period shares stock and warrants. Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Threshold market value as per Nasdaq capital market listing standards Threshold Market Value As Per Nasdaq Capital Market Listing Standards Threshold market value as per nasdaq capital market listing standards. Combined purchase price Purchase Price Of Warrants Purchase price of warrants. Entity Entity [Domain] Cover [Abstract] Original Term Loan and Convertible Note Financing Original Term Loan and Convertible Note Financing [Member] Original term loan and convertible note financing. Product and Service [Domain] 2018 Stock Incentive Plan Two Thousand Eighteen Stock Incentive Plan [Member] Two thousand eighteen stock incentive plan. Measurement Basis Fair Value By Measurement Basis [Axis] Non-accountable expense allowance Non-accountable Expense Allowance Non-accountable expense allowance. Finished goods Inventory, Finished Goods, Gross Accretion/ Interest Accrued Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Accretion Interest Or Accrued Fair value measurement with unobservable inputs reconciliations recurring basis liability accretion interest or accrued. Accrued miscellaneous expenses Accrued Miscellaneous Expenses Current Accrued miscellaneous expenses current. Current liabilities: Liabilities Current [Abstract] Entity Address, Address Line Three Entity Address Address Line3 Development and commercialization services and relief's right percentage of profit Development and Commercialization Services and Relief's Right Percentage of Profit Development and commercialization services and relief's right percentage of profit. Maximum Maximum Maximum [Member] Warrants term Warrants and Rights Outstanding, Term Percentage of prepayment, on or after March 4, 2027 Debt Instrument Prepayment Percentage Due After Five Year Debt Instrument Prepayment Percentage Due, after five year. Additional Bend Lease Additional Bend Lease [Member] Additional bend lease. Bend Lease Bend Lease [Member] Bend lease. Convertible note payable, at fair value Convertible Long Term Notes Payable Net cash used in investing activities Net Cash Provided By Used In Investing Activities Furniture and Fixtures Furniture And Fixtures [Member] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] PPP Loan Paycheck Protection Program Loan [Member] Paycheck protection program loan. Schedule of Components of Inventory Schedule of Inventory, Current [Table Text Block] Level 3 Fair Value Inputs Level3 [Member] Summary of Stock-Based Compensation Expense Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block] Use of Estimates Use Of Estimates Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Debt instrument, basis spread on variable rate Debt Instrument Basis Spread On Variable Rate1 Percentage of purchaser's option Percentage Of Purchaser's Option Percentage of purchaser's option Principal payments in 2023 Long-Term Debt, Maturity, Remainder of Fiscal Year The Securities Class Action Securities Class Action [Member] Securities class action. Collaboration funding amount Collaboration Funding Amount Collaboration funding amount. First Development Payment First Development Payment [Member] First Development Payment. Common stock, shares authorized Common Stock Shares Authorized Short-Term Debt, Type Short Term Debt Type [Domain] Trading Symbol Trading Symbol Title of Individual Title Of Individual With Relationship To Entity [Domain] Subsequent Event Type Subsequent Event Type [Axis] Value of SWK Amendment Warrant Adjustments To Additional Paid In Capital Amendment Warrant Issued Adjustments to additional paid in capital amendment warrant issued. Repayment Occurs On Or After June 16, 2023 Repayment Occurs On Or After June 16 2023 [Member] Repayment Occurs On Or After June 16 2023. Balance Sheet Location [Axis] Bridge Loan Bridge Loan [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Accounts Payable, Current, Total Accounts payable Accounts Payable Current Other current and non-current assets Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets, Total Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Plan Name Plan Name [Axis] Assistance Publique - Hopitaux de Paris ("AP-HP") Assistance Publique Hopitaux De Paris [Member] Assistance Publique – Hôpitaux de Paris. Title of Individual Title Of Individual [Axis] Quarterly interest payment due Debt Instrument, Periodic Payment, Interest Board of Directors Director [Member] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Payment for commitment fees Payment For Commitment Fees Payment for commitment fees. Debt instrument, term Debt Instrument Term Common stock, par value Common Stock Par Or Stated Value Per Share Placement Agent Placement Agent [Member] Placement agent. Percentage of common stock outstanding Percentage Of Common Stock Outstanding Percentage of common stock outstanding. Common Warrants Common Warrants [Member] Common Warrants. Property and Equipment Property Plant And Equipment Disclosure [Text Block] Pre-modification Marathon Convertible Note Pre-modification Marathon Convertible Note [Member] Pre-modification marathon convertible note. Weighted Average Exercise Price, Options Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Fair Value Estimate Of Fair Value Fair Value Disclosure [Member] First SWK Warrant First SWK Warrant [Member] First SWK Warrant. Net profit split ratio Net Profit Split Ratio Net profit split ratio. Debt Instrument [Line Items] Debt Instrument [Line Items] Long-Term Debt, Type Longterm Debt Type [Domain] Common stock dilutive securities Securities excluded from computation of net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Percentage of development and commercialization services Percentage Of Development And Commercialization Services Percentage of development and commercialization services.